Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 65/100

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Tuesday, November 25, 2025 1 min read
Key Takeaway: Invivyd, Inc. has announced its participation in the upcoming 8th Annual Evercore Healthcare Conference scheduled for December 2, 2025. The company's management will engage in a fireside chat at the event, which will also be available via a live webcast. This appearance highlights Invivyd's commitment to transparency and communication with investors. The biopharmaceutical company is known for its focus on developing innovative solutions for viral infectious diseases, having received emergency use authorization for a monoclonal antibody from the U.S. FDA in March 2024.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd is actively participating in industry conferences, showcasing engagement.
  • The company has received emergency use authorization for a monoclonal antibody, highlighting its innovative capabilities.
  • The live webcast allows for widespread access to information about their developments.

Full Press Release Details

NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 2:35 p.m. ET in Miami, FL.
A live webcast of the fireside chat will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 90 days following the presentation.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
investors@invivyd.com

Frequently Asked Questions

When will Invivyd participate in the Evercore Healthcare Conference?

Invivyd will participate on December 2, 2025, at 2:35 p.m. ET.

How can I watch the Invivyd fireside chat?

The chat can be viewed live on Invivyd's investor website.

What is Invivyd's main focus as a biopharmaceutical company?

Invivyd focuses on providing protection from serious viral diseases, starting with SARS-CoV-2.

What authorization did Invivyd receive in March 2024?

Invivyd received emergency use authorization for a monoclonal antibody from the U.S. FDA.

Where can I find more information about Invivyd?

More information is available at Invivyd's official website, invivyd.com.

Tags: IVVD Viatris Investor Conferences Healthcare Invivyd Evercore Conference monoclonal antibody SARS-CoV-2 FDA EUA
Last updated: Nov 25, 2025